<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32989282</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1759-507X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Nephrology</Title>
          <ISOAbbreviation>Nat Rev Nephrol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>WNT-β-catenin signalling - a versatile player in kidney injury and repair.</ArticleTitle>
        <Pagination>
          <StartPage>172</StartPage>
          <EndPage>184</EndPage>
          <MedlinePgn>172-184</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41581-020-00343-w</ELocationID>
        <Abstract>
          <AbstractText>The WNT-β-catenin system is an evolutionary conserved signalling pathway that is of particular importance for morphogenesis and cell organization during embryogenesis. The system is usually suppressed in adulthood; however, it can be re-activated in organ injury and regeneration. WNT-deficient mice display severe kidney defects at birth. Transient WNT-β-catenin activation stimulates tissue regeneration after acute kidney injury, whereas sustained (uncontrolled) WNT-β-catenin signalling promotes kidney fibrosis in chronic kidney disease (CKD), podocyte injury and proteinuria, persistent tissue damage during acute kidney injury and cystic kidney diseases. Additionally, WNT-β-catenin signalling is involved in CKD-associated vascular calcification and mineral bone disease. The WNT-β-catenin pathway is tightly regulated, for example, by proteins of the Dickkopf (DKK) family. In particular, DKK3 is released by 'stressed' tubular epithelial cells; DKK3 drives kidney fibrosis and is associated with short-term risk of CKD progression and acute kidney injury. Thus, targeting the WNT-β-catenin pathway might represent a promising therapeutic strategy in kidney injury and associated complications.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Schunk</LastName>
            <ForeName>Stefan J</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University, Homburg/Saar, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Floege</LastName>
            <ForeName>Jürgen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology and Clinical Immunology, University Hospital, Rheinisch Westfälische Technische Hochschule (RWTH), Aachen, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fliser</LastName>
            <ForeName>Danilo</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University, Homburg/Saar, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Speer</LastName>
            <ForeName>Thimoteus</ForeName>
            <Initials>T</Initials>
            <Identifier Source="ORCID">0000-0002-2491-6393</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology and Clinical Immunology, University Hospital, Rheinisch Westfälische Technische Hochschule (RWTH), Aachen, Germany. timo.speer@uks.eu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Rev Nephrol</MedlineTA>
        <NlmUniqueID>101500081</NlmUniqueID>
        <ISSNLinking>1759-5061</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>29</Day>
          <Hour>5</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32989282</ArticleId>
        <ArticleId IdType="doi">10.1038/s41581-020-00343-w</ArticleId>
        <ArticleId IdType="pii">10.1038/s41581-020-00343-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nusse, R. &amp; Varmus, H. E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31, 99–109 (1982).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6297757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nusse, R. &amp; Clevers, H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28575679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edeling, M., Ragi, G., Huang, S., Pavenstadt, H. &amp; Susztak, K. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat. Rev. Nephrol. 12, 426–439 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27140856</ArticleId>
            <ArticleId IdType="pmc">5529143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karner, C. M. et al. Wnt9b signaling regulates planar cell polarity and kidney tubule morphogenesis. Nat. Genet. 41, 793–799 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19543268</ArticleId>
            <ArticleId IdType="pmc">2761080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacDonald, B. T., Tamai, K. &amp; He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9–26 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19619488</ArticleId>
            <ArticleId IdType="pmc">2861485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niehrs, C. &amp; Shen, J. Regulation of Lrp6 phosphorylation. Cell Mol. Life Sci. 67, 2551–2562 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20229235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clevers, H. &amp; Nusse, R. Wnt/beta-catenin signaling and disease. Cell 149, 1192–1205 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22682243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma, L. &amp; Wang, H. Y. Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2+ non-canonical pathway. J. Biol. Chem. 282, 28980–28990 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17684012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang, Y. &amp; Mlodzik, M. Wnt-Frizzled/planar cell polarity signaling: cellular orientation by facing the wind (Wnt). Annu. Rev. Cell Dev. Biol. 31, 623–646 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26566118</ArticleId>
            <ArticleId IdType="pmc">4673888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willert, K. et al. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature 423, 448–452 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12717451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harterink, M. &amp; Korswagen, H. C. Dissecting the Wnt secretion pathway: key questions on the modification and intracellular trafficking of Wnt proteins. Acta Physiol. 204, 8–16 (2012).</Citation>
        </Reference>
        <Reference>
          <Citation>Lorenowicz, M. J. &amp; Korswagen, H. C. Sailing with the Wnt: charting the Wnt processing and secretion route. Exp. Cell Res. 315, 2683–2689 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19559695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langton, P. F., Kakugawa, S. &amp; Vincent, J. P. Making, exporting, and modulating Wnts. Trends Cell Biol. 26, 756–765 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27325141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panakova, D., Sprong, H., Marois, E., Thiele, C. &amp; Eaton, S. Lipoprotein particles are required for Hedgehog and Wingless signalling. Nature 435, 58–65 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15875013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mulligan, K. A. et al. Secreted Wingless-interacting molecule (Swim) promotes long-range signaling by maintaining Wingless solubility. Proc. Natl Acad. Sci. USA 109, 370–377 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22203956</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanganello, E. et al. Filopodia-based Wnt transport during vertebrate tissue patterning. Nat. Commun. 6, 5846 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25556612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross, J. C., Chaudhary, V., Bartscherer, K. &amp; Boutros, M. Active Wnt proteins are secreted on exosomes. Nat. Cell Biol. 14, 1036–1045 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22983114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu, Y. K. &amp; Nusse, R. The Frizzled CRD domain is conserved in diverse proteins including several receptor tyrosine kinases. Curr. Biol. 8, R405–R406 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9637908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinson, K. I., Brennan, J., Monkley, S., Avery, B. J. &amp; Skarnes, W. C. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature 407, 535–538 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11029008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oishi, I. et al. The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway. Genes Cell 8, 645–654 (2003).</Citation>
        </Reference>
        <Reference>
          <Citation>Malinauskas, T., Aricescu, A. R., Lu, W., Siebold, C. &amp; Jones, E. Y. Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. Nat. Struct. Mol. Biol. 18, 886–893 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21743455</ArticleId>
            <ArticleId IdType="pmc">3430870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh, J. C. et al. A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398, 431–436 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10201374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joiner, D. M., Ke, J., Zhong, Z., Xu, H. E. &amp; Williams, B. O. LRP5 and LRP6 in development and disease. Trends Endocrinol. Metab. 24, 31–39 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23245947</ArticleId>
            <ArticleId IdType="pmc">3592934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niida, A. et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 23, 8520–8526 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15378020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agapova, O. A., Fang, Y., Sugatani, T., Seifert, M. E. &amp; Hruska, K. A. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int. 89, 1231–1243 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27165838</ArticleId>
            <ArticleId IdType="pmc">4868771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, Z. et al. (Pro)renin receptor is an amplifier of Wnt/beta-catenin signaling in kidney injury and fibrosis. J. Am. Soc. Nephrol. 28, 2393–2408 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5533230</ArticleId>
            <ArticleId IdType="pmc">5533230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riediger, F. et al. Prorenin receptor is essential for podocyte autophagy and survival. J. Am. Soc. Nephrol. 22, 2193–2202 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22034640</ArticleId>
            <ArticleId IdType="pmc">3279931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kinouchi, K. et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ. Res. 107, 30–34 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20570919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou, D., Tan, R. J., Zhou, L., Li, Y. &amp; Liu, Y. Kidney tubular beta-catenin signaling controls interstitial fibroblast fate via epithelial-mesenchymal communication. Sci. Rep. 3, 1878 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23698793</ArticleId>
            <ArticleId IdType="pmc">3662012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maarouf, O. H. et al. Paracrine Wnt1 drives interstitial fibrosis without inflammation by tubulointerstitial cross-talk. J. Am. Soc. Nephrol. 27, 781–790 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26204899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DiRocco, D. P., Kobayashi, A., Taketo, M. M., McMahon, A. P. &amp; Humphreys, B. D. Wnt4/beta-catenin signaling in medullary kidney myofibroblasts. J. Am. Soc. Nephrol. 24, 1399–1412 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23766539</ArticleId>
            <ArticleId IdType="pmc">3752942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beaton, H. et al. Wnt6 regulates epithelial cell differentiation and is dysregulated in renal fibrosis. Am. J. Physiol. Ren. Physiol. 311, F35–F45 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou, D. et al. Tubule-specific ablation of endogenous beta-catenin aggravates acute kidney injury in mice. Kidney Int. 82, 537–547 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22622501</ArticleId>
            <ArticleId IdType="pmc">3425732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, Z. et al. Beta-catenin promotes survival of renal epithelial cells by inhibiting Bax. J. Am. Soc. Nephrol. 20, 1919–1928 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19696224</ArticleId>
            <ArticleId IdType="pmc">2736777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha, D. et al. Lithium activates the Wnt and phosphatidylinositol 3-kinase Akt signaling pathways to promote cell survival in the absence of soluble survival factors. Am. J. Physiol. Ren. Physiol. 288, F703–F713 (2005).</Citation>
        </Reference>
        <Reference>
          <Citation>Nlandu-Khodo, S. et al. Tubular beta-catenin and FoxO3 interactions protect in chronic kidney disease. JCI Insight 5, e135454 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">7259539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo, C. et al. Wnt9a promotes renal fibrosis by accelerating cellular senescence in tubular epithelial cells. J. Am. Soc. Nephrol. 29, 1238–1256 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29440280</ArticleId>
            <ArticleId IdType="pmc">5875944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, X. et al. Activation of Wnt5a-Ror2 signaling associated with epithelial-to-mesenchymal transition of tubular epithelial cells during renal fibrosis. Genes Cell 18, 608–619 (2013).</Citation>
        </Reference>
        <Reference>
          <Citation>Strutz, F. &amp; Zeisberg, M. Renal fibroblasts and myofibroblasts in chronic kidney disease. J. Am. Soc. Nephrol. 17, 2992–2998 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17035610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou, D. et al. Tubule-derived Wnts are required for fibroblast activation and kidney fibrosis. J. Am. Soc. Nephrol. 28, 2322–2336 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28336721</ArticleId>
            <ArticleId IdType="pmc">5533232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou, D. et al. Fibroblast-specific beta-catenin signaling dictates the outcome of AKI. J. Am. Soc. Nephrol. 29, 1257–1271 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29343518</ArticleId>
            <ArticleId IdType="pmc">5875957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang, P. M., Nikolic-Paterson, D. J. &amp; Lan, H. Y. Macrophages: versatile players in renal inflammation and fibrosis. Nat. Rev. Nephrol. 15, 144–158 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30692665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin, S. L. et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc. Natl Acad. Sci. USA 107, 4194–4199 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20160075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu, X. et al. Opposing actions of renal tubular- and myeloid-derived porcupine in obstruction-induced kidney fibrosis. Kidney Int. 96, 1308–1319 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31585741</ArticleId>
            <ArticleId IdType="pmc">6875628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong, D. W. L. et al. Activated renal tubular Wnt/beta-catenin signaling triggers renal inflammation during overload proteinuria. Kidney Int. 93, 1367–1383 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29605095</ArticleId>
            <ArticleId IdType="pmc">5967994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lever, J. M. et al. Resident macrophages reprogram toward a developmental state after acute kidney injury. JCI Insight 4, e12553 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Feng, Y., Liang, Y., Ren, J. &amp; Dai, C. Canonical Wnt signaling promotes macrophage proliferation during kidney fibrosis. Kidney Dis. 4, 95–103 (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>Feng, Y. et al. Wnt/beta-catenin-promoted macrophage alternative activation contributes to kidney fibrosis. J. Am. Soc. Nephrol. 29, 182–193 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29021383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng, Y. et al. The signaling protein Wnt5a promotes TGFbeta1-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap/Taz. J. Biol. Chem. 293, 19290–19302 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30333225</ArticleId>
            <ArticleId IdType="pmc">6302175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou, D., Tan, R. J., Fu, H. &amp; Liu, Y. Wnt/beta-catenin signaling in kidney injury and repair: a double-edged sword. Lab. Invest. 96, 156–167 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26692289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terada, Y. et al. Expression and function of the developmental gene Wnt-4 during experimental acute renal failure in rats. J. Am. Soc. Nephrol. 14, 1223–1233 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12707392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao, L. et al. Sustained activation of Wnt/beta-catenin signaling drives AKI to CKD progression. J. Am. Soc. Nephrol. 27, 1727–1740 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Chen, S. et al. Tenascin-C protects against acute kidney injury by recruiting Wnt ligands. Kidney Int. 95, 62–74 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30409456</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, D., Dai, C., Li, Y. &amp; Liu, Y. Canonical Wnt/beta-catenin signaling mediates transforming growth factor-beta1-driven podocyte injury and proteinuria. Kidney Int. 80, 1159–1169 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21832980</ArticleId>
            <ArticleId IdType="pmc">4300105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shkreli, M. et al. Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nat. Med. 18, 111–119 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22138751</ArticleId>
            <ArticleId IdType="pmc">3272332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai, C. et al. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J. Am. Soc. Nephrol. 20, 1997–2008 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19628668</ArticleId>
            <ArticleId IdType="pmc">2736766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou, L. &amp; Liu, Y. Wnt/beta-catenin signalling and podocyte dysfunction in proteinuric kidney disease. Nat. Rev. Nephrol. 11, 535–545 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26055352</ArticleId>
            <ArticleId IdType="pmc">4869701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kato, H. et al. Wnt/beta-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J. Biol. Chem. 286, 26003–26015 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21613219</ArticleId>
            <ArticleId IdType="pmc">3138306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou, L. et al. Wnt/beta-catenin links oxidative stress to podocyte injury and proteinuria. Kidney Int. 95, 830–845 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30770219</ArticleId>
            <ArticleId IdType="pmc">6431566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang, L. et al. Calmodulin-dependent protein kinase II/cAMP response element-binding protein/Wnt/beta-catenin signaling cascade regulates angiotensin II-induced podocyte injury and albuminuria. J. Biol. Chem. 288, 23368–23379 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23803607</ArticleId>
            <ArticleId IdType="pmc">3743506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He, W., Kang, Y. S., Dai, C. &amp; Liu, Y. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J. Am. Soc. Nephrol. 22, 90–103 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21030600</ArticleId>
            <ArticleId IdType="pmc">3014038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergmann, C. et al. Polycystic kidney disease. Nat. Rev. Dis. Primers 4, 50 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6592047</ArticleId>
            <ArticleId IdType="pmc">6592047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lancaster, M. A. et al. Impaired Wnt-beta-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy. Nat. Med. 15, 1046–1054 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19718039</ArticleId>
            <ArticleId IdType="pmc">2895985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng, S. et al. The sorting nexin 3 retromer pathway regulates the cell surface localization and activity of a Wnt-activated polycystin channel complex. J. Am. Soc. Nephrol. 28, 2973–2984 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28620080</ArticleId>
            <ArticleId IdType="pmc">5619965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim, S. et al. The polycystin complex mediates Wnt/Ca<sup>2+</sup> signalling. Nat. Cell Biol. 18, 752–764 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27214281</ArticleId>
            <ArticleId IdType="pmc">4925210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papakrivopoulou, E., Dean, C. H., Copp, A. J. &amp; Long, D. A. Planar cell polarity and the kidney. Nephrol. Dial. Transpl. 29, 1320–1326 (2014).</Citation>
        </Reference>
        <Reference>
          <Citation>Simons, M. et al. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat. Genet. 37, 537–543 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15852005</ArticleId>
            <ArticleId IdType="pmc">3733333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otto, E. A. et al. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat. Genet. 34, 413–420 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12872123</ArticleId>
            <ArticleId IdType="pmc">3732175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, A. et al. Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD. JCI Insight 3, e95874 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">5922276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surendran, K., Schiavi, S. &amp; Hruska, K. A. Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J. Am. Soc. Nephrol. 16, 2373–2384 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15944336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He, W. et al. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 765–776 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19297557</ArticleId>
            <ArticleId IdType="pmc">2663839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao, J. et al. Wnt/beta-catenin/RAS signaling mediates age-related renal fibrosis and is associated with mitochondrial dysfunction. Aging Cell 18, e13004 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31318148</ArticleId>
            <ArticleId IdType="pmc">6718575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, S. Y. et al. Four-and-a-half LIM domains protein 2 is a coactivator of Wnt signaling in diabetic kidney disease. J. Am. Soc. Nephrol. 26, 3072–3084 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25855776</ArticleId>
            <ArticleId IdType="pmc">4657839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao, Y. et al. Wnt/beta-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome. Kidney Int. 95, 815–829 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30770217</ArticleId>
            <ArticleId IdType="pmc">6431558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang, P., Cai, Y., Soofi, A. &amp; Dressler, G. R. Activation of Wnt11 by transforming growth factor-beta drives mesenchymal gene expression through non-canonical Wnt protein signaling in renal epithelial cells. J. Biol. Chem. 287, 21290–21302 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22556418</ArticleId>
            <ArticleId IdType="pmc">3375550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nlandu-Khodo, S. et al. Blocking TGF-beta and beta-catenin epithelial crosstalk exacerbates CKD. J. Am. Soc. Nephrol. 28, 3490–3503 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28701516</ArticleId>
            <ArticleId IdType="pmc">5698068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiao, X. et al. Redirecting TGF-beta signaling through the beta-catenin/foxo complex prevents kidney fibrosis. J. Am. Soc. Nephrol. 29, 557–570 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29180394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satoh, M. et al. Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling. Am. J. Physiol. Ren. Physiol. 303, F1641–F1651 (2012).</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou, L., Li, Y., Zhou, D., Tan, R. J. &amp; Liu, Y. Loss of Klotho contributes to kidney injury by derepression of Wnt/beta-catenin signaling. J. Am. Soc. Nephrol. 24, 771–785 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23559584</ArticleId>
            <ArticleId IdType="pmc">3636797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng, R., Ding, L., He, X., Takahashi, Y. &amp; Ma, J. X. Interaction of PPARα with the canonic Wnt pathway in the regulation of renal fibrosis. Diabetes 65, 3730–3743 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27543085</ArticleId>
            <ArticleId IdType="pmc">5127249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madan, B. et al. Experimental inhibition of porcupine-mediated Wnt O-acylation attenuates kidney fibrosis. Kidney Int. 89, 1062–1074 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27083283</ArticleId>
            <ArticleId IdType="pmc">4834146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He, X. et al. Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway. Kidney Int. 91, 642–657 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27914705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao, S. et al. Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. J. Am. Soc. Nephrol. 22, 1642–1653 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21816937</ArticleId>
            <ArticleId IdType="pmc">3171936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoccali, C. et al. The systemic nature of CKD. Nat. Rev. Nephrol. 13, 344–358 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28435157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishnan, V., Bryant, H. U. &amp; Macdougald, O. A. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116, 1202–1209 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16670761</ArticleId>
            <ArticleId IdType="pmc">1451219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clement-Lacroix, P. et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc. Natl Acad. Sci. USA 102, 17406–17411 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16293698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu, X. et al. Osteocytes mediate the anabolic actions of canonical Wnt/beta-catenin signaling in bone. Proc. Natl Acad. Sci. USA 112, E478–E486 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25605937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holmen, S. L. et al. Essential role of beta-catenin in postnatal bone acquisition. J. Biol. Chem. 280, 21162–21168 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15802266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kramer, I. et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol. Cell Biol. 30, 3071–3085 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20404086</ArticleId>
            <ArticleId IdType="pmc">2876685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dallas, S. L., Prideaux, M. &amp; Bonewald, L. F. The osteocyte: an endocrine cell… and more. Endocr. Rev. 34, 658–690 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23612223</ArticleId>
            <ArticleId IdType="pmc">3785641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonewald, L. F. &amp; Johnson, M. L. Osteocytes, mechanosensing and Wnt signaling. Bone 42, 606–615 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18280232</ArticleId>
            <ArticleId IdType="pmc">2349095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Lierop, A. H., Appelman-Dijkstra, N. M. &amp; Papapoulos, S. E. Sclerostin deficiency in humans. Bone 96, 51–62 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27742500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, X. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860–869 (2008).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18269310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winkler, D. G. et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267–6276 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14633986</ArticleId>
            <ArticleId IdType="pmc">291840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wijenayaka, A. R. et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6, e25900 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21991382</ArticleId>
            <ArticleId IdType="pmc">3186800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grotewold, L., Theil, T. &amp; Ruther, U. Expression pattern of Dkk-1 during mouse limb development. Mech. Dev. 89, 151–153 (1999).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10559490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morvan, F. et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21, 934–945 (2006).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16753024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima, H. et al. Wnt modulators, SFRP-1, and SFRP-2 are expressed in osteoblasts and differentially regulate hematopoietic stem cells. Biochem. Biophys. Res. Commun. 390, 65–70 (2009).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19778523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ominsky, M. S. et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Miner. Res. 26, 1012–1021 (2011).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21542004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng, G., Chang-Qing, Z., Yi-Min, C. &amp; Xiao-Lin, L. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats. Int. Immunopharmacol. 24, 7–13 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25479724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin, H. et al. Anti-DKK1 antibody promotes bone fracture healing through activation of beta-catenin signaling. Bone 71, 63–75 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25263522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ominsky, M. S., Boyce, R. W., Li, X. &amp; Ke, H. Z. Effects of sclerostin antibodies in animal models of osteoporosis. Bone 96, 63–75 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27789417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moe, S. M. et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J. Bone Miner. Res. 30, 499–509 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25407607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang, Y. et al. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J. Am. Soc. Nephrol. 25, 1760–1773 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24578135</ArticleId>
            <ArticleId IdType="pmc">4116062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrillo-Lopez, N. et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int. 90, 77–89 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27165819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabbagh, Y. et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone Miner. Res. 27, 1757–1772 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22492547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang, J. C. et al. PTH differentially regulates expression of RANKL and OPG. J. Bone Miner. Res. 19, 235–244 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14969393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keller, H. &amp; Kneissel, M. SOST is a target gene for PTH in bone. Bone 37, 148–158 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15946907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellido, T. et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146, 4577–4583 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16081646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo, J. et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 11, 161–171 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20142103</ArticleId>
            <ArticleId IdType="pmc">2819982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulkarni, N. H. et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J. Cell Biochem. 95, 1178–1190 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15962290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malluche, H. H., Mawad, H. &amp; Monier-Faugere, M. C. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol. Dial. Transpl. 19, i9–i13 (2004).</Citation>
        </Reference>
        <Reference>
          <Citation>Yang, C. Y. et al. Circulating Wnt/beta-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol. Dial. Transpl. 30, 1356–1363 (2015).</Citation>
        </Reference>
        <Reference>
          <Citation>Ho, T. Y. et al. Evaluation of the association of Wnt signaling with coronary artery calcification in patients on dialysis with severe secondary hyperparathyroidism. BMC Nephrol. 20, 345 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31477034</ArticleId>
            <ArticleId IdType="pmc">6721332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albanese, I. et al. Role of noncanonical Wnt signaling pathway in human aortic valve calcification. Arterioscler. Thromb. Vasc. Biol. 37, 543–552 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27932350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai, T. et al. WNT/beta-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. Exp. Cell Res. 345, 206–217 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27321958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freise, C., Kretzschmar, N. &amp; Querfeld, U. Wnt signaling contributes to vascular calcification by induction of matrix metalloproteinases. BMC Cardiovasc. Disord. 16, 185 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27716072</ArticleId>
            <ArticleId IdType="pmc">5045611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shao, J. S. et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J. Clin. Invest. 115, 1210–1220 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15841209</ArticleId>
            <ArticleId IdType="pmc">1077175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Aly, Z. et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr<sup>-/-</sup> mice. Arterioscler. Thromb. Vasc. Biol. 27, 2589–2596 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17932314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang, H. et al. Indoxyl sulfate accelerates vascular smooth muscle cell calcification via microRNA-29b dependent regulation of Wnt/beta-catenin signaling. Toxicol. Lett. 284, 29–36 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29195902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grande, M. T. et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 21, 989–997 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26236989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lovisa, S. et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 21, 998–1009 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26236991</ArticleId>
            <ArticleId IdType="pmc">4587560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu, Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15, 1–12 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14694152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon-Tillaux, N. &amp; Hertig, A. Snail and kidney fibrosis. Nephrol. Dial. Transpl. 32, 224–233 (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou, B. P. et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6, 931–940 (2004).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15448698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yook, J. I., Li, X. Y., Ota, I., Fearon, E. R. &amp; Weiss, S. J. Wnt-dependent regulation of the E-cadherin repressor snail. J. Biol. Chem. 280, 11740–11748 (2005).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15647282</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsui, I. et al. Snail, a transcriptional regulator, represses nephrin expression in glomerular epithelial cells of nephrotic rats. Lab. Invest. 87, 273–283 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17260001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, C. &amp; Siragy, H. M. High glucose induces podocyte injury via enhanced (pro)renin receptor-Wnt-beta-catenin-snail signaling pathway. PLoS One 9, e89233 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24533170</ArticleId>
            <ArticleId IdType="pmc">3923071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li, X., Deng, W., Lobo-Ruppert, S. M. &amp; Ruppert, J. M. Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin. Oncogene 26, 4489–4498 (2007).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17297467</ArticleId>
            <ArticleId IdType="pmc">2233601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou, D. et al. Matrix metalloproteinase-7 is a urinary biomarker and pathogenic mediator of kidney fibrosis. J. Am. Soc. Nephrol. 28, 598–611 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27624489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan, R. J. &amp; Liu, Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am. J. Physiol. Ren. Physiol. 302, F1351–F1361 (2012).</Citation>
        </Reference>
        <Reference>
          <Citation>Villa-Morales, M. &amp; Fernandez-Piqueras, J. Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin. Ther. Targets 16, 85–101 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22239437</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu, C. et al. Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy. Curr. Med. Chem. 22, 2858–2870 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26119175</ArticleId>
            <ArticleId IdType="pmc">4863711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan, R. J. et al. Tubular injury triggers podocyte dysfunction by beta-catenin-driven release of MMP-7. JCI Insight 4, e122399 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">6975262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He, W. et al. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/beta-catenin activity in CKD. J. Am. Soc. Nephrol. 23, 294–304 (2012).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22095947</ArticleId>
            <ArticleId IdType="pmc">3269179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang, X. et al. Urinary matrix metalloproteinase 7 and prediction of IgA nephropathy progression. Am. J. Kidney Dis. 75, 384–393 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31606236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu, H. et al. Matrix metalloproteinase-7 protects against acute kidney injury by priming renal tubules for survival and regeneration. Kidney Int. 95, 1167–1180 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30878215</ArticleId>
            <ArticleId IdType="pmc">6478554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang, X. et al. Urinary matrix metalloproteinase-7 predicts severe AKI and poor outcomes after cardiac surgery. J. Am. Soc. Nephrol. 28, 3373–3382 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28698269</ArticleId>
            <ArticleId IdType="pmc">5661292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall, G., Wang, L. &amp; Spurney, R. F. TRPC channels in proteinuric kidney diseases. Cells 9, 44 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">7016871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang, L. et al. Gq signaling causes glomerular injury by activating TRPC6. J. Clin. Invest. 125, 1913–1926 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25844902</ArticleId>
            <ArticleId IdType="pmc">4463190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou, L. et al. Multiple genes of the renin-angiotensin system are novel targets of Wnt/beta-catenin signaling. J. Am. Soc. Nephrol. 26, 107–120 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25012166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Floege, J. Antagonism of canonical Wnt/beta-catenin signaling: taking RAS blockade to the next level? J. Am. Soc. Nephrol. 26, 3–5 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25012172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao, L. et al. Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction. Nephrol. Dial. Transpl. 34, 2042–2050 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Liu, Y. et al. Inhibition of PAI-1 attenuates perirenal fat inflammation and the associated nephropathy in high-fat diet-induced obese mice. Am. J. Physiol. Endocrinol. Metab. 316, E260–E267 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30532990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu, C., Zhang, J., Noble, N. A., Peng, X. R. &amp; Huang, Y. An additive effect of anti-PAI-1 antibody to ACE inhibitor on slowing the progression of diabetic kidney disease. Am. J. Physiol. Ren. Physiol. 311, F852–F863 (2016).</Citation>
        </Reference>
        <Reference>
          <Citation>Kobayashi, N. et al. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated beta1-integrin endocytosis. Am. J. Physiol. Ren. Physiol. 308, F614–F626 (2015).</Citation>
        </Reference>
        <Reference>
          <Citation>Glinka, A. et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391, 357–362 (1998).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9450748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao, B. et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411, 321–325 (2001).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11357136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollard, S. L. &amp; Holland, P. W. Evidence for 14 homeobox gene clusters in human genome ancestry. Curr. Biol. 10, 1059–1062 (2000).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10996074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luke, G. N. et al. Dispersal of NK homeobox gene clusters in amphioxus and humans. Proc. Natl Acad. Sci. USA 100, 5292–5295 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12704239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao, B. et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature 417, 664–667 (2002).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12050670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao, B. &amp; Niehrs, C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 302, 179–183 (2003).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12527209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Federico, G. et al. Tubular Dickkopf-3 promotes the development of renal atrophy and fibrosis. JCI Insight 1, e84916 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27699213</ArticleId>
            <ArticleId IdType="pmc">5033928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu, B. et al. A cytokine-like protein dickkopf-related protein 3 is atheroprotective. Circulation 136, 1022–1036 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28674110</ArticleId>
            <ArticleId IdType="pmc">5598907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Issa Bhaloo, S. et al. Binding of Dickkopf-3 to CXCR7 enhances vascular progenitor cell migration and degradable graft regeneration. Circ. Res. 123, 451–466 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29980568</ArticleId>
            <ArticleId IdType="pmc">6092110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren, S. et al. LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1. Proc. Natl Acad. Sci. USA 110, 1440–1445 (2013).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23302695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson, B. G. et al. Connective tissue growth factor domain 4 amplifies fibrotic kidney disease through activation of LDL receptor-related protein 6. J. Am. Soc. Nephrol. 28, 1769–1782 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28130402</ArticleId>
            <ArticleId IdType="pmc">5461793</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin, C. L. et al. Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J. Am. Soc. Nephrol. 21, 124–135 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20019166</ArticleId>
            <ArticleId IdType="pmc">2799277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu, M. et al. Genetic variation of DKK3 may modify renal disease severity in ADPKD. J. Am. Soc. Nephrol. 21, 1510–1520 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20616171</ArticleId>
            <ArticleId IdType="pmc">3013521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wong, D. W. et al. Downregulation of renal tubular Wnt/beta-catenin signaling by Dickkopf-3 induces tubular cell death in proteinuric nephropathy. Cell Death Dis. 7, e2155 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27010856</ArticleId>
            <ArticleId IdType="pmc">4823961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lipphardt, M. et al. Dickkopf-3 in aberrant endothelial secretome triggers renal fibroblast activation and endothelial-mesenchymal transition. Nephrol. Dial. Transpl. 34, 49–62 (2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Schunk, S. J., Speer, T., Petrakis, I. &amp; Fliser, D. Dickkopf 3 — a novel biomarker of the ‘kidney injury continuum’. Nephrol. Dial. Transplant. https://doi.org/10.1093/ndt/gfaa003 (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>Zewinger, S. et al. Dickkopf-3 (DKK3) in urine identifies patients with short-term risk of eGFR Loss. J. Am. Soc. Nephrol. 29, 2722–2733 (2018).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30279273</ArticleId>
            <ArticleId IdType="pmc">6218861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rauen, T. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 373, 2225–2236 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26630142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schunk, S. J. et al. Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study. Lancet 394, 488–496 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31202596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zarbock, A. et al. Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA 313, 2133–2141 (2015).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26024502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24382002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27641143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Langdahl, B. L. et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390, 1585–1594 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28755782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. 377, 1417–1427 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28892457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatterjee, S. &amp; Sil, P. C. Targeting the crosstalks of Wnt pathway with Hedgehog and Notch for cancer therapy. Pharmacol. Res. 142, 251–261 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30826456</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
